Personalized AI health app VerilyMe is visualizing expanded eye health education in a new partnership with eye health-focused drugmaker Bausch + Lomb.  | The partnership marks Basuch + Lomb's foray ...

After coming up short in trials with two orexin type 2 receptor (OX2R) selective agonists, Takeda has scored with oveporexton ...

In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior rejections and agency leadership shakeups.  | In a remarkable turnaround, ...

In his first earnings call just days after becoming Sarepta Therapeutics' CEO, Michael Severino recognized that the rare ...

Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change ...

Fujifilm Biotechnologies passed the leadership reins to Maja Pedersen, adding president to her current role as COO while former Chief Executive Lars Petersen transitions to a strategic advisor ...

HIV drugmaker ViiV Healthcare is helping prospective HIV prevention or treatment users to make a choice that will help them later down the line in its “Do It For Future You” campaign.  | ViiV ...

Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to ...

Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. approval for its mRNA-based influenza vaccine.  | Despite a major curveball thrown by the ...

AstraZeneca and CSPC Pharmaceutical are strengthening their partnership by establishing a new biologics manufacturing joint ...

News of the unconfirmed deal talks drew major investor pushback on AZ’s side, with the British drugmaker’s stock sliding nearly 9% following the Financial Times report. The company’s London-listed ...

It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...